Immunic Shares Are Trading Higher After the Company Announced the Presentation of Data at the ECTRIMS 40th Congress, Highlighting Its Lead Asset, Nuclear Receptor Related 1 Activator, Vidofludimus Calcium's Therapeutic Potential in Multiple Sclerosis.
Immunic Shares Are Trading Higher After the Company Announced the Presentation of Data at the ECTRIMS 40th Congress, Highlighting Its Lead Asset, Nuclear Receptor Related 1 Activator, Vidofludimus Calcium's Therapeutic Potential in Multiple Sclerosis.
Immunic股票交易上漲。公司宣佈在第40屆ECTRIMS大會上發佈了一份數據報告，重點展示了其主力產品核受體相關1激活劑Vidofludimus Calcium在多發性硬化症的治療潛力。
Immunic Shares Are Trading Higher After the Company Announced the Presentation of Data at the ECTRIMS 40th Congress, Highlighting Its Lead Asset, Nuclear Receptor Related 1 Activator, Vidofludimus Calcium's Therapeutic Potential in Multiple Sclerosis.
Immunic股票交易上漲。公司宣佈在第40屆ECTRIMS大會上發佈了一份數據報告，重點展示了其主力產品核受體相關1激活劑Vidofludimus Calcium在多發性硬化症的治療潛力。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。